Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 3,580 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: patch Clear all

Conditions: Coronary Artery Disease
Interventions: Not listed
Lead sponsor: Global Genomics Group, LLC; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 29
States / cities: Huntsville, Alabama • Tucson, Arizona • Roseville, California + 22 more

Conditions: Diltiazem Skin Sensitivity.
Interventions: Diltiazem Hydrochloride 2% Cream, Vehicle Cream, 0.1% solution of sodium lauryl sulfate (SLS), Saline (0.9%); Drug
Lead sponsor: Ventrus Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Paramus, New Jersey

Conditions: Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma
Interventions: Pembrolizumab, MK-0482 + Pembrolizumab, MK-4830 + Pembrolizumab; Biological · Combination Product
Lead sponsor: Presage Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 11
States / cities: Sacramento, California • Atlanta, Georgia • Shreveport, Louisiana + 8 more

Conditions: Smoking
Interventions: Counseling, Self-help guide, Pharmacotherapy, Genetic feedback, verbal, Genetic feedback, printed; Behavioral · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Menlo Park, California • Stanford, California • Seattle, Washington

Conditions: Pancreatic Cystic Lesions
Interventions: Not listed
Lead sponsor: Amplified Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Indianapolis, Indiana • Boston, Massachusetts • New Brunswick, New Jersey

Conditions: Non-Small-Cell-Lung Cancer (NSCLC)
Interventions: 18F-FMISO, PET/CT; Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Vitiligo, Depigmented Scars, Depigmentation
Interventions: MKTP (melanocyte keratinocyte transplant procedure), Collagen Dressing, Vaseline Impregnated Gauze, Carbon Dioxide Laser, Dermabrasion; Procedure · Device
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Aneurysm, Dissection, Aortic Root Aneurysm, Aortic Root Dissection, Carotid Artery Injuries, Aortic Arch, Bypass Extremity Graft, Occlusive Vascular Disease, Aortic Diseases
Interventions: Gelsoft Plus Vascular Graft, Vascular Bypass Graft, Cardiovascular Patch, Gelweave Vascular Graft, Gelweave Valsalva Vascular Graft; Device
Lead sponsor: Vascutek Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2037
U.S. locations: 10
States / cities: Aurora, Colorado • Tampa, Florida • Indianapolis, Indiana + 7 more

Conditions: Locally Recurrent Prostate Cancer
Interventions: HDR Brachytherapy; Radiation
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 2
States / cities: Maywood, Illinois • Charlottesville, Virginia

Conditions: Smoking, Smoking, Cigarette, Smoking, Tobacco, Betel Chewer's Mucosa, Tobacco Use, Tobacco Smoking, Alcohol Drinking, Smokeless Tobacco Hyperkeratosis
Interventions: mHealth; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 5,122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Vascular; Lesion, Central Nervous System, Brain Tumor, Cerebral Aneurysm, Cerebral AVM
Interventions: GLOW800, indocyanine green (ICG); Device · Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Melanoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma of the Skin, Sarcoma of the Skin, Basal Cell Cancer of the Skin, Breast Cancer
Interventions: Poly-ICLC; Drug
Lead sponsor: Nina Bhardwaj; Other
Eligibility: 14 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Positive-Pressure Respiration, Communication
Interventions: F2S Communicator, Non-functioning Communicator; Device · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Coronary Artery Disease
Interventions: FFR/CFR and IVUS; Device
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 100 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Cincinnati, Ohio

Conditions: Pancreatic Cancer
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Anorexia Nervosa, Osteoporosis
Interventions: estradiol 0.045 mg/levonorgestrel 0.015mg; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 25 Years to 50 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alzheimer Disease
Interventions: Transdermal estradiol, Medroxyprogesterone, Placebo Patch, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 55 Years to 90 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Relapsing Multiple Sclerosis
Interventions: Remibrutinib oral treatment, Ocrelizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 45
States / cities: Scottsdale, Arizona • Irvine, California • Washington D.C., District of Columbia + 40 more

Conditions: Lung Neoplasm
Interventions: Computed Tomography, Electronic Health Record Review, Endobronchial Ultrasound Bronchoscopy; Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Smoking, Tobacco
Interventions: Counseling, Nicotine patch, Community Resource; Behavioral · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years to 80 Years
Enrollment: 642 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 6
States / cities: Boston, Massachusetts • Newton, Massachusetts • Oak Bluffs, Massachusetts + 1 more

Conditions: Tobacco Smoking
Interventions: Nicotine Patch, E-cigarette; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Coronary Arterial Disease (CAD)
Interventions: Intravascular Lithotripsy; Device
Lead sponsor: Shockwave Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 28
States / cities: La Jolla, California • San Francisco, California • Littleton, Colorado + 19 more

Conditions: Smoking, Cigarette
Interventions: JUUL, Treatment As Usual; Device · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 21 Years to 99 Years
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Prostate Cancer
Interventions: Pyruvate (13C), MRI; Drug · Device
Lead sponsor: Rahul Aggarwal; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

GLOBAL Clinical Study

Topical Safety Study of Topical Diltiazem Hydrochloride

PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS

Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial.

A Study for the PanCystPro Assay in the Management of Pancreatic Cystic Lesions

Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients

Comparative Study Using Dermabrasion vs CO2 Laser & Collagen Dressing vs Vaseline Gauze in MKTP

PANTHER Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches

Focal Salvage HDR Brachytherapy for Locally Recurrent Prostate Cancer in Patients Treated With Prior Radiotherapy

The Efficacy of Conventional Screening Versus mHealth Screening in Early Detection of Oral Potentially Malignant Disorders and Oral Cancer Amongst the Rural Population of Varanasi: A Prospective and Blinded Study

Intraoperative Fluorescence With Augmented Reality

Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)

Determining the Benefits of Improving Communication in BPAP/CPAP Users

Measurements to Assess Severity of Epicardial Stenoses

Validation of a Mouse Model of Pancreatic Carcinogenesis

Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa

Alzheimer's Disease: Therapeutic Potential of Estrogen

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Feasibility of Mobile-CT-Assisted Bronchoscopy for the Diagnosis of Lung Lesion

Assessing the Integration of Tobacco Cessation Treatment Into Lung Cancer Screening (LCS)

E-cigarettes to Promote Smoking Reduction Among Individuals With Schizophrenia

FORWARD CAD IDE Study

Switching to a Vaping Device: Evaluating Risk Reduction Among Quitline Treatment Failures

Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies